Spots Global Cancer Trial Database for A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
Official Title: A Phase II/III Randomized, Open-Label Clinical Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic Cancer Following Chemotherapy Failure
Study ID: NCT03721744
Conditions
Study Description
Brief Summary: This is a Phase II/III Randomized, Open-Label Clinical Study of GB201 in Combination with Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic Cancer Following Chemotherapy Failure
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Beijng Cancer Hospital, Beijing, Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Chinese PLA General Hospital, Beijing, Beijing, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
Guangdong General Hospital, Guangzhou, Guangdong, China
SUN YAT-SEN University Cancer Center, Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
Henan Cancer Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Union Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
People's Hospital of Hunan Province, Changsha, Hunan, China
The Third Xianya Hospital of Central South University, Changsha, Hunan, China
The 81 Hospital of the Chinese People Liberation Army, Nanjing, Jiangsu, China
Nantong Tumor Hospital, Nantong, Jiangsu, China
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
Shandong Cancer Hospital, Jinan, Shandong, China
East Hospital of Tongji University, Shanghai, Shanghai, China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Huashan Hospital Fudan University, Shanghai, Shanghai, China
Shanghai General Hospital, Shanghai, Shanghai, China
Xin Hua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, China
Tianjin Medical University Cancer Institute Hospital, Tianjin, Tianjin, China
Sir Run Shaw Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China
The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
The First Hospital of Jiaxing, Jiaxing, Zhejiang, China
Institut de Cancerologie de Lorraine, Bourgogne, , France
Unité de Recherche Clinique en Cancérologie, Institut de cancérologie et d'hématologie, Brest, , France
Centre Antoine Lacassagne, Nice, , France
Hospital Universitari Vall d'Hebron, Barcelona, , Spain
Hospital Universitario HMN Sanchinarro, Madrid, , Spain
Hospital Universitario La Paz, Madrid, , Spain
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
